| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于治疗与MASP-2依赖性补体活化相关的疾病的方法 | CN200780020670.8 | 2007-03-27 | CN101460195A | 2009-06-17 | H·施维布勒; C·M·施托弗; C·E·泰德富德; J·B·帕伦特; T·富吉塔 |
| 一方面，本发明提供抑制有生命的受治疗者的MASP－2依赖性补体活化作用的方法。该方法包括将MASP－2抑制剂按有效抑制MASP－2依赖性补体活化的量给予有需要的受治疗者的步骤。在一些实施方案中，所述MASP－2抑制剂抑制与MASP－2介导的替代补体途径活化有关的细胞损伤，同时保持免疫系统的经典(Clq依赖性)途径成分的完整。另一方面，本发明提供用于抑制凝集素依赖性补体活化作用的组合物，所述组合物包含治疗有效量的MASP－2抑制剂和药学上可接受的载体。 | ||||||
| 2 | 用于抑制MASP‑2依赖的补体活化的组合物 | CN201280032866.X | 2012-05-04 | CN103687620B | 2017-10-13 | T.杜德勒; W.R.贡博茨; J.B.帕伦特; C.E.特德福德; A.卡夫利; U.B.黑格曼; H.里尔森; S.基普里贾诺夫 |
| 本发明涉及抗MASP‑2抑制性抗体和包括该抗体的组合物，用于抑制MASP‑2依赖的补体活化的不良效果。在一方面，本发明提供了分离的人单克隆抗体或其抗原结合片段，其结合人MASP‑2，所述抗体包括：（i）包括CDR‑H1、CDR‑H2和CDR‑H3序列的重链可变区；和（ii）包括CDR‑L1、CDR‑L2和CDR‑L3序列的轻链可变区，其中所述重链可变区CDR‑H3序列包括设置与B因子形成额外的替代途径C3转化酶（C3bBb）的氨基酸序列。替代途径C3转化酶通过结合备解素被稳定化。备解素使替代途径C3转化酶的半衰期延长六到十倍。向替代途径C3转化酶添加C3b导致替代途径C5转化酶的形成。 | ||||||
| 3 | 用于治疗与MASP-2依赖性补体活化相关的疾病的方法 | CN201310478423.X | 2007-03-27 | CN103705921A | 2014-04-09 | H.施维布勒; C.M.施托弗; C.E.泰德富德; J.B.帕伦特; T.富吉塔 |
| 一方面，本发明提供抑制有生命的受治疗者的MASP-2依赖性补体活化作用的方法。该方法包括将MASP-2抑制剂按有效抑制MASP-2依赖性补体活化的量给予有需要的受治疗者的步骤。在一些实施方案中，所述MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化有关的细胞损伤，同时保持免疫系统的经典(Clq依赖性)途径成分的完整。另一方面，本发明提供用于抑制凝集素依赖性补体活化作用的组合物，所述组合物包含治疗有效量的MASP-2抑制剂和药学上可接受的载体。 | ||||||
| 4 | 通过抑制MASP-2依赖性补体活化治疗弥散性血管内凝血的方法 | CN201080056358.6 | 2010-10-15 | CN102781471B | 2016-10-12 | H.施维布尔; T.A.杜德勒; C.E.特德福德; J.B.帕伦特; G.A.德莫普罗斯 |
| 一方面，本发明提供抑制有生命的受试者中MASP‑2依赖性补体活化的作用的方法。在一个实施方案中，本发明提供治疗患有诸如弥散性血管内凝血的补体介导凝血障碍的受试者的方法。该方法包括将有效抑制MASP‑2依赖性补体活化的量的MASP‑2抑制剂给予有需要的受试者的步骤。在一些实施方案中，所述MASP‑2抑制剂抑制与MASP‑2介导的替代补体途径活化有关的细胞损伤，同时保持免疫系统的经典(Clq依赖性)途径成分的完整。另一方面，本发明提供用于抑制凝集素依赖性补体活化的作用的组合物，所述组合物包含治疗有效量的MASP‑2抑制剂和药学上可接受的载体。 | ||||||
| 5 | 用于抑制MASP-2依赖的补体活化的组合物 | CN201280032866.X | 2012-05-04 | CN103687620A | 2014-03-26 | T.杜德勒; W.R.贡博茨; J.B.帕伦特; C.E.特德福德; A.卡夫利; U.B.黑格曼; H.里尔森; S.基普里贾诺夫 |
| 本发明涉及抗MASP-2抑制性抗体和包括该抗体的组合物，用于抑制MASP-2依赖的补体活化的不良效果。在一方面，本发明提供了分离的人单克隆抗体或其抗原结合片段，其结合人MASP-2，所述抗体包括：（i）包括CDR-H1、CDR-H2和CDR-H3序列的重链可变区；和（ii）包括CDR-L1、CDR-L2和CDR-L3序列的轻链可变区，其中所述重链可变区CDR-H3序列包括设置与B因子形成额外的替代途径C3转化酶（C3bBb）的氨基酸序列。替代途径C3转化酶通过结合备解素被稳定化。备解素使替代途径C3转化酶的半衰期延长六到十倍。向替代途径C3转化酶添加C3b导致替代途径C5转化酶的形成。 | ||||||
| 6 | 用于治疗与MASP-2依赖性补体活化相关的疾病的方法 | CN200780020670.8 | 2007-03-27 | CN101460195B | 2013-11-20 | H·施维布勒; C·M·施托弗; C·E·泰德富德; J·B·帕伦特; T·富吉塔 |
| 一方面，本发明提供抑制有生命的受治疗者的MASP-2依赖性补体活化作用的方法。该方法包括将MASP-2抑制剂按有效抑制MASP-2依赖性补体活化的量给予有需要的受治疗者的步骤。在一些实施方案中，所述MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化有关的细胞损伤，同时保持免疫系统的经典(Clq依赖性)途径成分的完整。另一方面，本发明提供用于抑制凝集素依赖性补体活化作用的组合物，所述组合物包含治疗有效量的MASP-2抑制剂和药学上可接受的载体。 | ||||||
| 7 | 通过抑制MASP-2依赖性补体活化治疗弥散性血管内凝血的方法 | CN201080056358.6 | 2010-10-15 | CN102781471A | 2012-11-14 | H.施维布尔; T.A.杜德勒; C.E.特德福德; J.B.帕伦特; G.A.德莫普罗斯 |
| 一方面，本发明提供抑制有生命的受试者中MASP-2依赖性补体活化的作用的方法。在一个实施方案中，本发明提供治疗患有诸如弥散性血管内凝血的补体介导凝血障碍的受试者的方法。该方法包括将有效抑制MASP-2依赖性补体活化的量的MASP-2抑制剂给予有需要的受试者的步骤。在一些实施方案中，所述MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化有关的细胞损伤，同时保持免疫系统的经典(Clq依赖性)途径成分的完整。另一方面，本发明提供用于抑制凝集素依赖性补体活化的作用的组合物，所述组合物包含治疗有效量的MASP-2抑制剂和药学上可接受的载体。 | ||||||
| 8 | MASP－2,一种补体固定酶及其用途 | CN01814642.2 | 2001-07-13 | CN1449440A | 2003-10-15 | 詹斯·C·詹斯尼厄斯; 斯蒂芬·蒂尔 |
| 本发明涉及基本上纯的甘露聚糖－结合凝集素相关的丝氨酸蛋白酶－2(MASP－2)多肽及其片段，以及编码该多肽的核酸。而且，本发明涉及使用基本上纯的、含有衍生自甘露聚糖－结合凝集素相关的丝氨酸蛋白酶－2(MASP－2)或其功能性同系物的氨基酸序列的多肽在制备药物组合物以及含有MASP－2和/或MASP－2片段的药物组合物中的用途。另外，本发明涉及MASP－2抑制剂和含有该抑制剂的药物组合物。本发明也包括检测MASP－2核酸表达的方法。 | ||||||
| 9 | Compositions for inhibiting MASP-2 dependent complement activation | US15263876 | 2016-09-13 | US10047165B2 | 2018-08-14 | Thomas Dudler; Wayne R. Gombotz; James Brian Parent; Clark E. Tedford; Anita Kavlie; Urs Beat Hagemann; Herald Reiersen; Sergej Kiprijanov |
| The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation. | ||||||
| 10 | Compositions and Methods of Inhibiting MASP-3 for the Treatment of Various Diseases and Disorders | US15665030 | 2017-07-31 | US20180140697A1 | 2018-05-24 | W. Jason Cummings; Gregory A. Demopulos; Thomas Dudler; Hans-Wilhelm Schwaeble; Larry W. Tjoelker; Christi L. Wood; Munehisa Yabuki |
| The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation. | ||||||
| 11 | Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation | US15376134 | 2016-12-12 | US20170233494A1 | 2017-08-17 | Hans-Wilhelm Schwaeble; Thomas Dudler; Clark E. Tedford; James Brian Parent; Gregory A. Demopulos |
| In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | ||||||
| 12 | Masp-2, a complement-fixing enzyme, and uses for it | US10332713 | 2001-07-13 | US07112414B2 | 2006-09-26 | Jens Christian Jensenius; Steffen Thiel |
| The present invention relates to substantially pure mannan-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Furthermore, the present invention relates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositions comprising MASP-2 and/or MASP-2 fragments. In addition the present invention relates to inhibitors of MASP-2 and pharmaceutical compositions comparing such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention. | ||||||
| 13 | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation | US12905972 | 2010-10-15 | US08652477B2 | 2014-02-18 | Hans-Wilhelm Schwaeble; Thomas Dudler; Clark E. Tedford; James B. Parent; Gregory A. Demopulos |
| In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | ||||||
| 14 | METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | US12905972 | 2010-10-15 | US20110091450A1 | 2011-04-21 | Hans-Wilhelm Schwaeble; Thomas Dudler; Clark E. Tedford; James B. Parent; Gregory A. Demopulos |
| In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | ||||||
| 15 | Methods for treating conditions associated with lectin-dependent complement activation | US11150887 | 2005-06-09 | US20060018896A1 | 2006-01-26 | Hans-Wilhelm Schwaeble; Cordula Stover; Clark Tedford; James Parent; Teizo Fujita |
| In one aspect, the invention provides methods of inhibiting the effects of lectin-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MAp19 inhibitory agent effective to inhibit lectin-dependent complement activation. In some embodiments, the MAp19 inhibitory agent inhibits cellular injury associated with lectin-mediated complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides MAp19 specific antibodies that do not bind to MASP-2 and methods of producing MAp19 specific antibodies. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MAp19 inhibitory agent and a pharmaceutically acceptable carrier. | ||||||
| 16 | Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation | US15950633 | 2018-04-11 | US20180291112A1 | 2018-10-11 | Hans-Wilhelm Schwaeble; Thomas Dudler; Clark E. Tedford; James Brian Parent; Gregory A. Demopulos |
| In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | ||||||
| 17 | Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation | US14168785 | 2014-01-30 | US20140205598A1 | 2014-07-24 | Hans-Wilhelm Schwaeble; Thomas Dudler; Clark E. Tedford; James Brian Parent; Gregory A. Demopulos |
| In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | ||||||
| 18 | Masp-2,a complement-fixing enzyme, and uses for it | US10332713 | 2003-07-03 | US20040038297A1 | 2004-02-26 | Jens Christian Jensenius; Steffen Thiel |
| The present invention relates to substantially pure mannin-binding lectin associated serine protease-2 (MASP-2) polypeptides and fragments thereof as well as nucleic acids encoding such polpeptides. Futhermone, the present invention realates to uses of a substantially pure polypeptide comprising amino acid sequences derived from mannan-binding lectin associated serine protease-2 (MASP2) or a functional homologue thereof for the production of a pharmaceutical composition as well as pharmaceutical compositons comprising MASP-2 and/or MASP-2 fragments. In addition the present invetion relates to inhibitors of MASP-2 and pharmaceutical compositiosn compring such inhibitors. Methods for detecting MASP-2 nucleic acid expression are included in the invention. | ||||||
| 19 | MASP−2依存性補体活性化に関連した状態を治療するための方法 | JP2018523485 | 2016-11-09 | JP2018533592A | 2018-11-15 | デモピュロス グレゴリー エイ.; ドゥドラー トーマス; シュワーエブル ハンス−ウィルヘルム |
| 本発明は、一局面において、造血幹細胞移植に関連するTMAに罹患しているヒト対象においてMASP-2依存性補体活性化の効果を阻害する方法を提供する。前記方法は、その必要がある対象に、MASP-2依存性補体活性化を阻害するのに有効な量のMASP-2阻害物質を投与する工程を含む。 |
||||||
| 20 | Method for treating a condition associated with complement activation Masp-2-dependent | JP2009504382 | 2007-03-27 | JP5567328B2 | 2014-08-06 | ハンス−ウィルヘルム シュウェブル，; コーデュラ マーガレット シュテーバー，; クラーク イー． テッドフォード，; ジェームス ビー． パーレン，; 禎三 藤田 |
QQ群二维码
意见反馈
意见反馈